Erythropoietin reduces pathogenic humoral immunity by inhibiting T Follicular Helper cell differentiation and function

A large fraction of organ transplant recipients develop anti-donor antibodies (DSA), with accelerated graft loss and increased mortality. We tested the hypothesis that erythropoietin (EPO) reduces DSA formation by inhibiting T follicular helper (TFH) cells. We measured DSA levels, splenic TFH, TFR cells, germinal center (GC), and class switched B cells, in murine models of allogeneic sensitization, allogeneic transplantation and in parent-to-F1 models of graft versus host disease (GVHD). We quantified the same cell subsets and specific antibodies, upon EPO or vehicle treatment, in wild type mice and animals lacking EPO receptor selectively on T or B cells, immunized with T-independent or T-dependent stimuli. In vitro, we tested the EPO effect on TFH induction. We isolated TFH and TFR cells to perform in vitro assay and clarify their role. EPO reduced DSA levels, GC, class switched B cells, and increased the TFR/TFH ratio in the heart transplanted mice and in two GVHD models. EPO did also reduce TFH and GC B cells in SRBC-immunized mice, while had no effect in TNP-AECM-FICOLL-immunized animals, indicating that EPO inhibits GC B cells by targeting TFH cells. EPO effects were absent in T cells EPOR conditional KO mice, confirming that EPO affects TFH in vivo through EPOR. In vitro, EPO affected TFH induction through an EPO-EPOR-STAT5-dependent pathway. Suppression assay demonstrated that the reduction of IgG antibodies was dependent on TFH cells, sustaining the central role of the subset in this EPO-mediated mechanism. In conclusion, EPO prevents DSA formation in mice through a direct suppression of TFH. Development of DSA is associated with high risk of graft rejection, giving our data a strong rationale for studies testing the hypothesis that EPO administration prevents their formation in organ transplant recipients. Our findings provide a foundation for testing EPO as a treatment of antibody mediated disease processes.

Urine-derived Renal Epithelial Cells from kidney transplanted patients: phenotype, immunomodulatory properties, and effect of the exposition to NGAL

During kidney transplant procedure transplanted organs can undergo ischaemia reperfusion phenomena, often associated with the onset of acute kidney damage, loss of kidney function and rejection. These events promote cell turnover to replace damaged cells and preserve kidney function, thus cells deriving from nephrons structures are highly voided in urine. Urine derived cells represents a promising cell source since they can be easily isolated and cultured. The aim of this project was to characterise Urine-derived Renal Epithelial Cells (URECs) from transplanted kidney and to evaluate how these cells react to the co-culture with immune cells. URECs expressed typical markers of kidney tubule epithelial cells (Cytokeratin and CD13), and a subpopulation of these cells expressed CD24 and CD133, which are markers of kidney epithelial progenitor cells. The expression of immunosuppressive molecules as HLA-G and CD73 was also observed. As matter of fact, during the co-culture with PBMCs, UREC suppressed the proliferation of CD4 and CD8 Lymphocytes and reduce the T helper 1 subset, while increasing the T regulatory counterpart. Also, preliminary data observed in this study indicated that the exposition to kidney damage associated molecule, such as NGAL, could significantly affect UREC viability and immunomodulatory capacity. These results add new information about the phenotype of urine cells obtained after kidney transplant and reveal that these cells show promising immunomodulatory properties, suggesting their potential application in personalized cell therapy approaches.